Korea-U.S. FTA Takes Effect March 15; Pharma Companies Assess Changing Landscape
This article was originally published in PharmAsia News
Executive Summary
Nearly six years after negotiations started, the bilateral FTA between South Korea and the U.S. finally takes effect in March amid worries in Korea that it could ultimately harm generic-dependent local pharma companies.
You may also be interested in...
Pharma Industry Applauds Final Push For Ratification Of Korea-U.S. FTA, Patent Linkage, Transparency, Among Benefits
SEOUL - South Korean Prime Minister Kim Hwang-sik called on cabinet ministers to ratify Korea's free trade agreement with the United States during the country's National Assembly session Oct. 4
Revised U.S.-Korea FTA Grants Three-year Grace Period To Korean Generic Drug Makers
SEOUL - Despite discontent among opposition parties in South Korea with the recently revised Free Trade Agreement with the U.S., Korea's generic drug makers are welcoming new supplementary agreements, which they say would give them a three-year grace period during which they could launch generic versions of patented products
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.